Novartis AG Long-Term Investments 2010-2024 | NVS
Novartis AG long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
- Novartis AG long-term investments for the quarter ending June 30, 2024 were $2.126B, a 12.62% decline year-over-year.
- Novartis AG long-term investments for 2023 were $2.812B, a 10.1% increase from 2022.
- Novartis AG long-term investments for 2022 were $2.554B, a 21.2% decline from 2021.
- Novartis AG long-term investments for 2021 were $3.241B, a 74.14% decline from 2020.
Novartis AG Annual Long-Term Investments
(Millions of US $) |
| 2023 |
$2,812 |
| 2022 |
$2,554 |
| 2021 |
$3,241 |
| 2020 |
$12,533 |
| 2019 |
$8,644 |
| 2018 |
$10,697 |
| 2017 |
$17,613 |
| 2016 |
$16,500 |
| 2015 |
$17,780 |
| 2014 |
$10,152 |
| 2013 |
$10,748 |
| 2012 |
$9,957 |
| 2011 |
$9,560 |
| 2010 |
$10,225 |
| 2009 |
$20,426 |
Novartis AG Quarterly Long-Term Investments
(Millions of US $) |
| 2024-06-30 |
$2,126 |
| 2024-03-31 |
$2,582 |
| 2023-12-31 |
$2,812 |
| 2023-09-30 |
$2,122 |
| 2023-06-30 |
$2,433 |
| 2023-03-31 |
$2,555 |
| 2022-12-31 |
$2,554 |
| 2022-09-30 |
$2,491 |
| 2022-06-30 |
$2,580 |
| 2022-03-31 |
$2,906 |
| 2021-12-31 |
$3,241 |
| 2021-09-30 |
$12,347 |
| 2021-06-30 |
$12,014 |
| 2021-03-31 |
$11,628 |
| 2020-12-31 |
$12,533 |
| 2020-09-30 |
$11,603 |
| 2020-06-30 |
$11,050 |
| 2020-03-31 |
$8,303 |
| 2019-12-31 |
$8,644 |
| 2019-09-30 |
$8,284 |
| 2019-06-30 |
$8,204 |
| 2019-03-31 |
$10,122 |
| 2018-12-31 |
$10,697 |
| 2018-09-30 |
$10,807 |
| 2018-06-30 |
$10,359 |
| 2018-03-31 |
$10,521 |
| 2017-12-31 |
$17,613 |
| 2017-09-30 |
|
| 2017-06-30 |
$27,926 |
| 2017-03-31 |
|
| 2016-12-31 |
$16,500 |
| 2016-09-30 |
|
| 2016-06-30 |
|
| 2016-03-31 |
|
| 2015-12-31 |
$17,780 |
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
$10,152 |
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
$10,748 |
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
$9,957 |
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
$9,560 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
$10,225 |
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
$20,426 |
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$237.043B |
$45.440B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
